Eli Lilly achieved a 45% year-over-year revenue increase of 45% to $12.73 billion in the first quarter of 2025[1][2]. Growth was primarily driven by sales volume, which contributed 53 percentage points, partially offset by a 6% decline in prices[1][2]. Key drugs such as Mounjaro, Zepbound and Verzenio generated a combined $7.52 billion in sales[1]. Mounjaro reached $3.84 billion, with a growth of 113%[1]. Gross margin increased to $10.50 billion, or 48%[1]. The company plans to invest more than $50 billion in U.S. manufacturing, including a new $3.5 billion plant in Pennsylvania to produce drugs such as tirsepatide and retatrutide[5]. Orforglipron, an oral drug, has successfully completed the first of five late-phase trials in diabetes and obesity[1].